search
Back to results

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow (REAL 8)

Primary Purpose

SGA, Turner Syndrome, Noonan Syndrome, ISS

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Somapacitan
Norditropin®
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for SGA, Turner Syndrome, Noonan Syndrome, ISS

Eligibility Criteria

2 Years - 10 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Informed consent of parent or legally acceptable representative of participant and child assent, as age appropriate must be obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  2. No prior exposure to growth promoting therapy, including but not limited to growth hormone, IGF-I and ghrelin analogues.

    Applicable to children with SGA:

  3. Born small for gestational age (birth length below -2 SDS OR birth weight below -2 SDS OR both) (according to national standards).
  4. Prepubertal children:

    1. Boys:

      • Age above or equal to 2 years and 26 weeks and below 11.0 years at screening.
      • Testis volume below 4 mL
    2. Girls:

      • Age above or equal to 2 years and 26 weeks and below 10.0 years at screening.
      • Tanner stage 1 for breast development: No palpable glandular breast tissue)
  5. Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention.
  6. Impaired height velocity defined as annualised height velocity below the 50th percentile for chronological age and sex according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.
  7. Body Mass Index below the 95th percentile according to Centers for Disease Control and Prevention, Body Mass Index-for-age growth charts.

    Applicable to girls with TS:

  8. Confirmed diagnosis of TS by 30-cell (or more) lymphocyte chromosomal analysis.*
  9. Prepubertal girls:

    • Age above or equal to 2 years and 26 weeks and below 10.0 years at screening.
    • Tanner stage 1 for breast development: No palpable glandular breast tissue)
  10. Impaired height defined as at least 2.0 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention.
  11. Historical height measured 6-18 months prior to screening.
  12. Thyroid hormone replacement therapy should be adequate and stable for at least 90 days prior to randomisation, if applicable.

    Applicable to children with NS:

  13. Clinical diagnosis of NS according to van der Burgt score list
  14. Prepubertal children:

    1. Boys:

      • Age above or equal to 2 years and 26 weeks and below 11.0 years at screening.
      • Testis volume below 4 mL
    2. Girls:

      • Age above or equal to 2 years and 26 weeks and below 10.0 years at screening.
      • Tanner stage 1 for breast development: No palpable glandular breast tissue)
  15. Impaired height defined as at least 2.0 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention.
  16. Historical height measured 6-18 months prior to screening.
  17. Thyroid hormone replacement therapy should be adequate and stable for at least 90 days prior to randomisation, if applicable.

    Applicable to children with ISS:

  18. Prepubertal children:

    1. Boys:

      • Age above or equal to 2 years and 26 weeks and below 11.0 years at screening.
      • Testis volume below 4 mL
    2. Girls:

      • Age above or equal to 2 years and 26 weeks and below 10.0 years at screening.
      • Tanner stage 1 for breast development: No palpable glandular breast tissue)
  19. Bone age:

    1. Boys:

      • Bone age below or equal to 12 years.
      • Bone age not delayed or advanced more than 2 years compared to chronological age.
    2. Girls:

      • Bone age below or equal to 11 years.
      • Bone age not delayed or advanced more than 2 years compared to chronological age.
  20. Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention.
  21. Historical height measured 6-18 months prior to screening.
  22. One normal GH secretion (GH peak above 7 ng/mL) during GH stimulation test performed within 18 months prior to screening or if such a test is not available for children with ISS, a test should be performed as part of the screening assessments and the result must be available prior to randomisation.

    • If a 30-cell count is not available for patients with TS, a test should be done, and results must be available prior to randomisation.

Exclusion criteria:

  1. Known or suspected hypersensitivity to study intervention(s) or related products.
  2. Previous randomisation into same sub-study in this study.
  3. Receipt of any investigational medicinal product within 3 months before screening or participation in another clinical study at the time of randomisation.
  4. Children with suspected or confirmed growth hormone deficiency according to local practice.
  5. Children diagnosed with diabetes mellitus or screening values from the central laboratory of

    1. fasting plasma glucose above or equal to 126 mg/dL (7.0 mmol/L) or
    2. HbA1c above or equal to 6.5%.
  6. Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
  7. Children requiring inhaled glucocorticoid therapy at a dose greater than 400 µg/day of inhaled budesonide or equivalent (i.e., 250 µg/day for fluticasone propionate) for longer than 4 consecutive weeks within the last 12 months prior to screening.
  8. Concomitant administration of other treatments that may have an effect on growth, e.g., but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder (ADHD).
  9. Diagnosis of attention deficit hyperactivity disorder (ADHD).
  10. History or known presence of malignancy including intracranial tumours.
  11. History or known presence of active Hepatitis B or Hepatitis C (exceptions to this exclusion criterion is the presence of antibodies due to vaccination against Hepatitis B).
  12. Any disorder, which in the investigator's opinion, might jeopardise participant's safety or compliance with the protocol.
  13. The participant or the parent/legally acceptable representative is likely to be non-compliant in respect to study conduct, as judged by the investigator.
  14. Current treatment with sex hormones or aromatase inhibitors.
  15. Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements, such as, but not limited to:

    1. Known family history of skeletal dysplasia.
    2. Significant spinal abnormalities including but not limited to scoliosis, kyphosis and spina bifida variants.
    3. Any other disorder/condition that can cause short stature such as, but not limited to, psychosocial deprivation, nutritional disorders, chronic systemic illness and chronic renal disease.

Applicable to children with SGA:

  1. TS (including mosaicism).
  2. NS.
  3. Hormonal deficiencies.
  4. Children who are small due to malnutrition defined as -2 standard deviations according to standards. 0¬-5 years: weight for height on World Health Organisation Multicentre Growth Reference Study 2006. Above 5 years: World Health Organisation 2007 Body Mass Index.
  5. Known chromosomal aneuploidy or significant gene mutations causing medical 'syndromes' with short stature, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, skeletal dysplasias, abnormal SHOX gene analysis or absence of GH receptors.

Applicable to children with TS:

  1. NS.
  2. Mosaicism below 10%.
  3. TS with Y-chromosome mosaicism where gonadectomy has not been performed.
  4. NYHA class II or above or requiring medication for any heart condition.
  5. Coeliac disease where participant is not stable on gluten free diet for the previous 12 months prior to screening.

Applicable to children with NS:

  1. TS (including mosaicism).
  2. Noonan-related disorders: Noonan syndrome with multiple lentigines (formerly called 'LEOPARD' syndrome), Noonan syndrome with loose anagen hair, cardiofaciocutaneous syndrome (CFC), Costello syndrome, neurofibromatosis type 1 (NF1) and Legius syndrome. Molecular genetic panel testing results must be available prior to randomisation to exclude these.
  3. Coeliac disease where participant is not stable on gluten free diet for the previous 12 months prior to screening.

Applicable to children with ISS:

  1. TS (including mosaicism).
  2. NS.
  3. Hormonal deficiencies.
  4. Born small for gestational age (defined as birth length below -2 SDS OR birth weight below -2 SDS OR both) (according to national standards).
  5. Known chromosomal aneuploidy or significant gene mutations causing medical 'syndromes' with short stature, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, skeletal dysplasias, abnormal SHOX gene analysis or absence of GH receptors.

Sites / Locations

  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting
  • Novo Nordisk Investigational SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Somapacitan

Norditropin®

Arm Description

Participants will receive Somapacitan for 156 weeks

Participants will receive Norditropin® for 52 weeks (main phase) and Somapacitan for 104 weeks (extension phase)

Outcomes

Primary Outcome Measures

Height velocity reported separately for small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS) and idiopathic short stature (ISS)
Measured in centimeter per year (cm/year)

Secondary Outcome Measures

Change in Height standard deviation scores (SDS) reported separately for SGA, TS, NS and ISS
Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline.
Change in Height Velocity SDS reported separately for SGA, TS, NS and ISS
Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline.
Change in bone age reported separately for SGA, TS and NS
Measured in ratio
Change in bone age for ISS
Measured in ratio
Change in insulin-like growth factor 1 (IGF-1) SDS reported separately for SGA, TS, NA and ISS
Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline.
Change in insulin-like growth factor binding protein-3 (IGFBP-3) SDS reported separately for SGA, TS, NA and ISS
Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline.
Change in fasting plasma glucose reported separately for SGA, TS, NS and ISS
Measured in millimoles per litre (mmol/L)
Change in homeostatic model assessment-B (HOMA-B) reported separately for SGA, TS, NS and ISS
Measured in percentage (%)
Change in homeostatic model assessment of insulin resistance (HOMAIR) reported separately for SGA, TS, NS and ISS
Measured in %
Change in glycated haemoglobin (HbA1c) reported separately for SGA, TS, NS and ISS
Measured in percentage of HbA1c
Weekly average somapacitan concentration (Cavg) based on population PK analysis
Measured in nanograms per milliliter (ng/mL)
Change in fasting plasma glucose reported separately for SGA, TS, NS and ISS
Measured in mmol/L
Change in homeostatic model assessment-B (HOMA-B) reported separately for SGA, TS, NS and ISS
Measured in %
Change in homeostatic model assessment of insulin resistance (HOMA-IR) reported separately for SGA, TS, NS and ISS
Measured in %
Change in glycated haemoglobin (HbA1c) reported separately for SGA, TS, NS and ISS
Measured in percentage of HbA1c

Full Information

First Posted
April 8, 2022
Last Updated
September 21, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT05330325
Brief Title
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
Acronym
REAL 8
Official Title
A Study Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® as Well as Evaluating Long-term Safety of Somapacitan in a Basket Study Design in Children With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 10, 2022 (Actual)
Primary Completion Date
August 2, 2024 (Anticipated)
Study Completion Date
September 17, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study compares two medicines for treatment of children born small and who stay small, or with Turner Syndrome, Noonan Syndrome, or idiopathic short stature. The purpose of the study is to see how well treatment with somapacitan works compared to treatment with Norditropin®. Somapacitan is a new medicine, and Norditropin® is a medicine doctors can already prescribe in some countries. The study will last for about 3 years. The participants will either get somapacitan once a week for 3 years or Norditropin® once a day for 1 year followed by somapacitan once a week for 2 years. Which treatment the participants get is decided by chance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
SGA, Turner Syndrome, Noonan Syndrome, ISS

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
399 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Somapacitan
Arm Type
Experimental
Arm Description
Participants will receive Somapacitan for 156 weeks
Arm Title
Norditropin®
Arm Type
Active Comparator
Arm Description
Participants will receive Norditropin® for 52 weeks (main phase) and Somapacitan for 104 weeks (extension phase)
Intervention Type
Drug
Intervention Name(s)
Somapacitan
Intervention Description
Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
Intervention Type
Drug
Intervention Name(s)
Norditropin®
Intervention Description
Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
Primary Outcome Measure Information:
Title
Height velocity reported separately for small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS) and idiopathic short stature (ISS)
Description
Measured in centimeter per year (cm/year)
Time Frame
From baseline (week 0) to visit 7 (week 52)
Secondary Outcome Measure Information:
Title
Change in Height standard deviation scores (SDS) reported separately for SGA, TS, NS and ISS
Description
Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline.
Time Frame
From baseline (week 0) to visit 7 (week 52)
Title
Change in Height Velocity SDS reported separately for SGA, TS, NS and ISS
Description
Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline.
Time Frame
From baseline (week 0) to visit 7 (week 52)
Title
Change in bone age reported separately for SGA, TS and NS
Description
Measured in ratio
Time Frame
From baseline (week 0) to visit 7 (week 52)
Title
Change in bone age for ISS
Description
Measured in ratio
Time Frame
From screening (visit 1) to visit 7 (week 52)
Title
Change in insulin-like growth factor 1 (IGF-1) SDS reported separately for SGA, TS, NA and ISS
Description
Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline.
Time Frame
From baseline (week 0) to visit 7 (week 52).
Title
Change in insulin-like growth factor binding protein-3 (IGFBP-3) SDS reported separately for SGA, TS, NA and ISS
Description
Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline.
Time Frame
From baseline (week 0) to visit 7 (week 52).
Title
Change in fasting plasma glucose reported separately for SGA, TS, NS and ISS
Description
Measured in millimoles per litre (mmol/L)
Time Frame
From screening (visit 1) to visit 7 (week 52)
Title
Change in homeostatic model assessment-B (HOMA-B) reported separately for SGA, TS, NS and ISS
Description
Measured in percentage (%)
Time Frame
From screening (visit 1) to visit 7 (week 52)
Title
Change in homeostatic model assessment of insulin resistance (HOMAIR) reported separately for SGA, TS, NS and ISS
Description
Measured in %
Time Frame
From screening (visit 1) to visit 7 (week 52)
Title
Change in glycated haemoglobin (HbA1c) reported separately for SGA, TS, NS and ISS
Description
Measured in percentage of HbA1c
Time Frame
From screening (visit 1) to visit 7 (week 52)
Title
Weekly average somapacitan concentration (Cavg) based on population PK analysis
Description
Measured in nanograms per milliliter (ng/mL)
Time Frame
From visit 3 (week 4) to visit 7 (week 52)
Title
Change in fasting plasma glucose reported separately for SGA, TS, NS and ISS
Description
Measured in mmol/L
Time Frame
From screening (visit 1) to visit 15 (week 156)
Title
Change in homeostatic model assessment-B (HOMA-B) reported separately for SGA, TS, NS and ISS
Description
Measured in %
Time Frame
From screening (visit 1) to visit 15 (week 156)
Title
Change in homeostatic model assessment of insulin resistance (HOMA-IR) reported separately for SGA, TS, NS and ISS
Description
Measured in %
Time Frame
From screening (visit 1) to visit 15 (week 156)
Title
Change in glycated haemoglobin (HbA1c) reported separately for SGA, TS, NS and ISS
Description
Measured in percentage of HbA1c
Time Frame
From screening (visit 1) to visit 15 (week 156)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Informed consent of parent or legally acceptable representative of participant and child assent, as age appropriate must be obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. No prior exposure to growth promoting therapy, including but not limited to growth hormone, IGF-I and ghrelin analogues. Applicable to children with SGA: Born small for gestational age (birth length below -2 SDS OR birth weight below -2 SDS OR both) (according to national standards). Prepubertal children: Boys: Age above or equal to 2 years and 26 weeks and below 11.0 years at screening. Testis volume below 4 mL Girls: Age above or equal to 2 years and 26 weeks and below 10.0 years at screening. Tanner stage 1 for breast development: No palpable glandular breast tissue) Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention. Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and sex according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening. Body Mass Index below the 95th percentile according to Centers for Disease Control and Prevention, Body Mass Index-for-age growth charts. Applicable to girls with TS: Confirmed diagnosis of TS by 30-cell (or more) lymphocyte chromosomal analysis.* Prepubertal girls: Age above or equal to 2 years and 26 weeks and below 10.0 years at screening. Tanner stage 1 for breast development: No palpable glandular breast tissue) Impaired height defined as at least 2.0 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention. Historical height measured 6-18 months prior to screening. Thyroid hormone replacement therapy should be adequate and stable for at least 90 days prior to randomization, if applicable. Applicable to children with NS: Clinical diagnosis of NS according to van der Burgt score list Prepubertal children: Boys: Age above or equal to 2 years and 26 weeks and below 11.0 years at screening. Testis volume below 4 mL Girls: Age above or equal to 2 years and 26 weeks and below 10.0 years at screening. Tanner stage 1 for breast development: No palpable glandular breast tissue) Impaired height defined as at least 2.0 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention. Historical height measured 6-18 months prior to screening. Thyroid hormone replacement therapy should be adequate and stable for at least 90 days prior to randomization, if applicable. Applicable to children with ISS: Prepubertal children: Boys: Age above or equal to 2 years and 26 weeks and below 11.0 years at screening. Testis volume below 4 mL Girls: Age above or equal to 2 years and 26 weeks and below 10.0 years at screening. Tanner stage 1 for breast development: No palpable glandular breast tissue) Bone age: Boys: Bone age below or equal to 12 years. Bone age not delayed or advanced more than 2 years compared to chronological age. Girls: Bone age below or equal to 11 years. Bone age not delayed or advanced more than 2 years compared to chronological age. Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and sex at screening according to the standards of Centers for Disease Control and Prevention. Historical height measured 6-18 months prior to screening. One normal GH secretion (GH peak above 7 ng/mL) during GH stimulation test performed within 18 months prior to screening or if such a test is not available for children with ISS, a test should be performed as part of the screening assessments and the result must be available prior to randomization. If a 30-cell count is not available for patients with TS, a test should be done, and results must be available prior to randomization. Exclusion criteria: Known or suspected hypersensitivity to study intervention(s) or related products. Previous randomization into same sub-study in this study. Receipt of any investigational medicinal product within 3 months before screening or participation in another clinical study at the time of randomization. Children with suspected or confirmed growth hormone deficiency according to local practice. laboratory of fasting plasma glucose above or equal to 126 mg/dL (7.0 mmol/L) or HbA1c above or equal to 6.5%. Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening. Children requiring inhaled glucocorticoid therapy at a dose greater than 400 µg/day of inhaled budesonide or equivalent (i.e., 250 µg/day for fluticasone propionate) for longer than 4 consecutive weeks within the last 12 months prior to screening. Concomitant administration of other treatments that may have an effect on growth, e.g., but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder (ADHD). Diagnosis of attention deficit hyperactivity disorder (ADHD). History or known presence of any malignancy, intracranial tumour, or intracranial cyst. History or known presence of active Hepatitis B or Hepatitis C (exceptions to this exclusion criterion is the presence of antibodies due to vaccination against Hepatitis B). Any disorder, which in the investigator's opinion, might jeopardize participant's safety or compliance with the protocol. The participant or the parent/legally acceptable representative is likely to be non-compliant in respect to study conduct, as judged by the investigator. Current treatment with sex hormones or aromatase inhibitors. Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements, such as, but not limited to: Known family history of skeletal dysplasia. Significant spinal abnormalities including but not limited to scoliosis, kyphosis and spina bifida variants. Any other disorder/condition that can cause short stature such as, but not limited to, psychosocial deprivation, nutritional disorders, chronic systemic illness and chronic renal disease. Applicable to children with SGA: TS (including mosaicism). NS. Hormonal deficiencies. Children who are small due to malnutrition defined as -2 standard deviations according to standards. 0¬-5 years: weight for height on World Health Organization Multicentre Growth Reference Study 2006. Above 5 years: World Health Organization 2007 Body Mass Index. Known chromosomal aneuploidy or significant gene mutations causing medical 'syndromes' with short stature, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, skeletal dysplasias, abnormal SHOX gene analysis or absence of GH receptors. Applicable to children with TS: NS. Mosaicism below 10%. TS with Y-chromosome mosaicism where gonadectomy has not been performed. NYHA class II or above or requiring medication for any heart condition. Coeliac disease where participant is not stable on gluten free diet for the previous 12 months prior to screening. Applicable to children with NS: TS (including mosaicism). Noonan-related disorders: Noonan syndrome with multiple lentigines (formerly called 'LEOPARD' syndrome), Noonan syndrome with loose anagen hair, cardiofaciocutaneous syndrome (CFC), Costello syndrome, neurofibromatosis type 1 (NF1) and Legius syndrome. Molecular genetic panel testing results must be available prior to randomisation to exclude these. Coeliac disease where participant is not stable on gluten free diet for the previous 12 months prior to screening. Applicable to children with ISS: TS (including mosaicism). NS. Hormonal deficiencies. Born small for gestational age (defined as birth length below -2 SDS OR birth weight below -2 SDS OR both) (according to national standards). Known chromosomal aneuploidy or significant gene mutations causing medical 'syndromes' with short stature, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, skeletal dysplasias, abnormal SHOX gene analysis or absence of GH receptors.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Novo Nordisk
Phone
(+1) 866-867-7178
Email
clinicaltrials@novonordisk.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Transparency dept. 2834
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Sacramento
State/Province
California
ZIP/Postal Code
95821
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Centennial
State/Province
Colorado
ZIP/Postal Code
80112
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Greenwood Village
State/Province
Colorado
ZIP/Postal Code
80111-2803
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Wilmington
State/Province
Delaware
ZIP/Postal Code
19803
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010-2978
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30318
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Boise
State/Province
Idaho
ZIP/Postal Code
83712
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Idaho Falls
State/Province
Idaho
ZIP/Postal Code
83404-7596
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55454
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Saint Paul
State/Province
Minnesota
ZIP/Postal Code
55102
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64108
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07962
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Buffalo
State/Province
New York
ZIP/Postal Code
14203
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Mineola
State/Province
New York
ZIP/Postal Code
11501
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27610
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Akron
State/Province
Ohio
ZIP/Postal Code
44308
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75235
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Shavano Park
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Marshfield
State/Province
Wisconsin
ZIP/Postal Code
54449
Country
United States
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Dornbirn
ZIP/Postal Code
6850
Country
Austria
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Linz
ZIP/Postal Code
4020
Country
Austria
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
St. Poelten
ZIP/Postal Code
A 3100
Country
Austria
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Vöcklabruck
ZIP/Postal Code
A 4840
Country
Austria
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Brussel
ZIP/Postal Code
1090
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Curitiba
State/Province
Parana
ZIP/Postal Code
80810-040
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
São Paulo
State/Province
Sao Paulo
ZIP/Postal Code
01228-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01223-001
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
São Paulo
State/Province
SP
ZIP/Postal Code
05403-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Pleven
ZIP/Postal Code
5800
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Plovdiv
ZIP/Postal Code
4002
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Sofia
ZIP/Postal Code
1606
Country
Bulgaria
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Sofia
ZIP/Postal Code
1606
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Varna
ZIP/Postal Code
9010
Country
Bulgaria
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L1
Country
Canada
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100045
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
LIU Zhou
State/Province
Guangxi
ZIP/Postal Code
545001
Country
China
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Sanya
State/Province
Hainan
ZIP/Postal Code
572032
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450018
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430019
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430030
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410007
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250021
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200062
Country
China
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200127
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610000
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Zagreb
ZIP/Postal Code
10 000
Country
Croatia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Helsinki
ZIP/Postal Code
00290
Country
Finland
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
ANGERS cedex 09
ZIP/Postal Code
49033
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
ANGERS cedex 09
ZIP/Postal Code
49033
Country
France
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bordeaux Cedex
ZIP/Postal Code
33076
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bordeaux Cedex
ZIP/Postal Code
33076
Country
France
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Le Kremelin-Bicêtre
ZIP/Postal Code
94270
Country
France
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Le Kremlin-bicetre
ZIP/Postal Code
94275
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
MARSEILLE Cédex 05
ZIP/Postal Code
13385
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Marseille
ZIP/Postal Code
13005
Country
France
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Novo Nordisk Investigational Site
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Frankfurt am Main
ZIP/Postal Code
60596
Country
Germany
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Homburg
ZIP/Postal Code
66421
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Homburg
ZIP/Postal Code
66424
Country
Germany
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Goudi/Athens
ZIP/Postal Code
115-27
Country
Greece
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Goudi/Athens
ZIP/Postal Code
115-27
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Haidari-Athens
ZIP/Postal Code
GR-12462
Country
Greece
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Patra
ZIP/Postal Code
26504
Country
Greece
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Thessaloniki
ZIP/Postal Code
GR 54642
Country
Greece
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Thessaloniki
ZIP/Postal Code
GR 54642
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Thessaloniki
ZIP/Postal Code
GR-54636
Country
Greece
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Thessaloniki
ZIP/Postal Code
GR-54636
Country
Greece
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Thessaloniki
ZIP/Postal Code
GR546-42
Country
Greece
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kochi
State/Province
Kerala
ZIP/Postal Code
682041
Country
India
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411001
Country
India
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
New Dehli
State/Province
New Delhi
ZIP/Postal Code
110029
Country
India
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Cork
Country
Ireland
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Cork
Country
Ireland
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Dublin
ZIP/Postal Code
D01 XD99
Country
Ireland
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Dublin
ZIP/Postal Code
D12 N512
Country
Ireland
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Dublin
ZIP/Postal Code
D24NR0A
Country
Ireland
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Beer Sheva
ZIP/Postal Code
84101
Country
Israel
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Petah Tikva
ZIP/Postal Code
49202
Country
Israel
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Zerifin
ZIP/Postal Code
70300
Country
Israel
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Firenze
ZIP/Postal Code
50139
Country
Italy
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Genova
ZIP/Postal Code
16147
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Milano
ZIP/Postal Code
20132
Country
Italy
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Napoli
ZIP/Postal Code
80138
Country
Italy
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Roma
ZIP/Postal Code
00165
Country
Italy
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Rome
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Fukuoka-shi, Fukuoka
ZIP/Postal Code
813-0017
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kobe-shi, Hyogo
ZIP/Postal Code
650-0047
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Nara-shi, Nara
ZIP/Postal Code
630-8581
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Niigata-shi, Niigata
ZIP/Postal Code
951 8520
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Okayama-shi, Okayama
ZIP/Postal Code
701-1192
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Osaka
ZIP/Postal Code
534-0021
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Osaka
ZIP/Postal Code
594-1101
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Sapporo, Hokkaido
ZIP/Postal Code
060-8648
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Shizuoka-shi, Shizuoka
ZIP/Postal Code
420-8660
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
113-8519
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
157 8535
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
160-8582
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Toyoake, Aichi
ZIP/Postal Code
470-1192
Country
Japan
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Sejong-si
ZIP/Postal Code
30099
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Yangsan
ZIP/Postal Code
50612
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Riga
ZIP/Postal Code
LV1004
Country
Latvia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kaunas
ZIP/Postal Code
LT-50161
Country
Lithuania
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kota Bharu
State/Province
Kelantan
ZIP/Postal Code
16150
Country
Malaysia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bandar Puncak Alam Selangor Darul Ehsan
ZIP/Postal Code
42300
Country
Malaysia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kuala Lumpur
ZIP/Postal Code
59100
Country
Malaysia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Puebla
ZIP/Postal Code
72190
Country
Mexico
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Rotterdam
ZIP/Postal Code
3015 GD
Country
Netherlands
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Rzeszow
State/Province
Podkarpackie Voivodeship
ZIP/Postal Code
35-301
Country
Poland
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Cracow
ZIP/Postal Code
30-663
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Cracow
ZIP/Postal Code
30-663
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Gdansk
ZIP/Postal Code
80-952
Country
Poland
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Lodz
ZIP/Postal Code
93-338
Country
Poland
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Szczecin
ZIP/Postal Code
71-252
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Szczecin
ZIP/Postal Code
71-252
Country
Poland
Individual Site Status
Withdrawn
Facility Name
Novo Nordisk Investigational Site
City
Zabrze
ZIP/Postal Code
41-800
Country
Poland
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Lisboa
ZIP/Postal Code
1169-045
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Lisboa
ZIP/Postal Code
1649-035
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Porto
ZIP/Postal Code
4050-651
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Vila Nova de Gaia
ZIP/Postal Code
4400-129
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Riyadh
ZIP/Postal Code
12713
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Riyadh
ZIP/Postal Code
14812
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Belgrade
ZIP/Postal Code
11070
Country
Serbia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Nis
ZIP/Postal Code
18 000
Country
Serbia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Nis
ZIP/Postal Code
18 000
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Novi Sad
ZIP/Postal Code
21000
Country
Serbia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Novi Sad
ZIP/Postal Code
21000
Country
Serbia
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Ljubljana
ZIP/Postal Code
1525
Country
Slovenia
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Ljubljana
ZIP/Postal Code
1525
Country
Slovenia
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1864
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0181
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Mayville
State/Province
KwaZulu-Natal
ZIP/Postal Code
4058
Country
South Africa
Individual Site Status
Not yet recruiting
Facility Name
Novo Nordisk Investigational Site
City
Westville
State/Province
KwaZulu-Natal
ZIP/Postal Code
3600
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Santiago de Compostela
State/Province
A Coruña
ZIP/Postal Code
15706
Country
Spain
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Boadilla del Monte
State/Province
Madrid
ZIP/Postal Code
28660
Country
Spain
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Esplugues de Llobregat
ZIP/Postal Code
08950
Country
Spain
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bangkok
ZIP/Postal Code
10400
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Chiang Mai
ZIP/Postal Code
50200
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Khon Kaen
ZIP/Postal Code
40002
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Hull
ZIP/Postal Code
HU3 2JZ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Liverpool
ZIP/Postal Code
L12 2AP
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
London
ZIP/Postal Code
SE1 7EH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Manchester
ZIP/Postal Code
M13 9WL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Novo Nordisk Investigational Site
City
Tooting
ZIP/Postal Code
SW17 0RE
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

We'll reach out to this number within 24 hrs